Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 809,311 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| CytomX Therapeutics Inc | CTMX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.63 | -12.28% | 4.50 | 06:35:29 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 5.13 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 5,686 | 809,311 | - | 1.04 - 5.85 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 06:36:07 | 1 | US$ 4.51 | USD |
CytomX Therapeutics (CTMX) Options Flow Summary
CytomX Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 347.41M | 67.72M | - | 101.21M | -569k | -0.01 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
CytomX Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CTMX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.61 | 5.85 | 1.58 | 5.11 | 41,529,720 | 2.89 | 179.50% |
| 1 Month | 2.18 | 5.85 | 1.58 | 4.99 | 10,799,625 | 2.32 | 106.42% |
| 3 Months | 1.43 | 5.85 | 1.38 | 4.50 | 4,547,644 | 3.07 | 214.69% |
| 6 Months | 1.09 | 5.85 | 1.09 | 4.30 | 2,283,029 | 3.41 | 312.84% |
| 1 Year | 1.72 | 5.85 | 1.04 | 4.00 | 1,266,644 | 2.78 | 161.63% |
| 3 Years | 9.12 | 9.64 | 1.04 | 3.37 | 1,269,713 | -4.62 | -50.66% |
| 5 Years | 9.35 | 15.44 | 1.04 | 4.43 | 979,472 | -4.85 | -51.87% |
CytomX Therapeutics Description
| CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. The company focuses on developing Probody therapeutics which addresses clinically-validated cancer targets in immuno-oncology that are difficult to drug and lead to concerns about damage to healthy tissues or toxicities. |
